US Long-Acting Bronchodilator Market Share 2019 Growth Challenges, Opportunities and Future Trends 2025

The US long-acting bronchodilator market is anticipated to grow at a substantial rate of 1.7% during the forecast period. The growth of the market of long-acting bronchodilator devices in the US is mainly driven by factors that include the growing prevalence of chronic diseases such as asthma, diabetes, respiratory lung diseases and so on. Asthma is chronic inflammation of the lung airways that causes breathlessness and coughing. The number of people with asthma grows every year in the US. According to CDC 2017, there were around 26 million asthma patients in the US, among which, nearly 18.9 million were adults and 7.1 million were children. Moreover, the prevalence of asthma in children is nearly 9.4% which is higher than that of adults accounting to around 7.7%, and higher in females nearly 9.2% than in males accounting to 7% of total asthma patients. This is one of the primary reasons for the high growth rate of the market within the country.

To Request a Sample of our Report on US Long-Acting Bronchodilator Market: https://www.omrglobal.com/request-sample/us-long-acting-bronchodilator-market

The US long-acting bronchodilator market is segmented on the basis of route of administration, application, and end-user. Based on the route of administration, the market is classified into oral, nasal, parenteral, and inhalation. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. The asthma disease application segment dominated the regional market in 2018 and is further estimated to follow the same trend over the forecast period. This is mainly due to the high prevalence of asthma in the country. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed. The homecare segment is estimated to share significant market share in the market.

(Get 15% Discount on Buying this Report)

A full Report of US Long-Acting Bronchodilator Market is Available @ https://www.omrglobal.com/industry-reports/us-long-acting-bronchodilator-market

US Long-Acting Bronchodilator Market Segmentation

By Route of Administration

· Oral

· Nasal

· Parenteral

· Inhalation

By Application

· Asthma

· Chronic Obstructive Pulmonary Disease (COPD)

By End-User

· Homecare

· Hospitals and Clinics

Company Profiles

· Adamis Pharmaceuticals Corp.

· AstraZeneca PLC

· Boehringer Ingelheim International GmbH

· GlaxoSmithKline PLC

· Novartis AG

· ResMed Corp.

· Pulmatrix Inc.

· Savara, Inc.

· Sunovion Pharmaceuticals

· Teva Pharmaceuticals Industries Ltd.

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.